Inappropriate glucagon and GLP-1 secretion in individuals with long-standing type 1 diabetes: effects of residual C-peptide.


Journal

Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777

Informations de publication

Date de publication:
04 2019
Historique:
received: 31 10 2018
accepted: 03 12 2018
pubmed: 7 1 2019
medline: 19 2 2020
entrez: 7 1 2019
Statut: ppublish

Résumé

Recent studies have demonstrated that residual beta cells may be present in some people with long-standing type 1 diabetes, but little is known about the potential impact of this finding on alpha cell function and incretin levels. This study aimed to evaluate whether insulin microsecretion could modulate glucagon and glucagon-like peptide-1 (GLP-1) responses to a mixed meal tolerance test (MMTT). Adults with type 1 diabetes onset after the age of 15 years (n = 29) underwent a liquid MMTT after an overnight fast. Insulin microsecretion was defined when peak C-peptide levels were >30 pmol/l using an ultrasensitive assay. Four individuals with recent-onset type 1 diabetes were included as controls. Glucagon and GLP-1 responses were analysed according to C-peptide patterns. We found comparable peak values, Δ The glucagon response to an MMTT in people with long-standing type 1 diabetes is not reduced by the presence of residual beta cells. The reduction of GLP-1 responses according to residual C-peptide levels suggests specific regulatory pathways.

Identifiants

pubmed: 30612138
doi: 10.1007/s00125-018-4804-y
pii: 10.1007/s00125-018-4804-y
doi:

Substances chimiques

Blood Glucose 0
C-Peptide 0
Incretins 0
Insulin 0
Glucagon-Like Peptide 1 89750-14-1
Glucagon 9007-92-5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

593-597

Références

N Engl J Med. 1986 May 22;314(21):1360-8
pubmed: 3517648
Diabetologia. 2012 Dec;55(12):3262-72
pubmed: 22965295
Diabetes Care. 2014 Apr;37(4):1076-82
pubmed: 24241790
Am J Physiol Endocrinol Metab. 2010 Apr;298(4):E832-7
pubmed: 20103744
Diabetologia. 2014 Jan;57(1):187-91
pubmed: 24121625
Diabetes Care. 2012 Mar;35(3):465-70
pubmed: 22355018
Diabetes. 1995 Jun;44(6):626-30
pubmed: 7789625
Diabetes. 2010 May;59(5):1202-10
pubmed: 20185817
Diabetes Care. 2015 Jun;38(6):979-88
pubmed: 25998290
Diabetes Care. 2016 Oct;39(10):1702-10
pubmed: 27506222
Cell. 2012 Sep 14;150(6):1223-34
pubmed: 22980982
Diabetes Care. 2008 Jul;31(7):1403-4
pubmed: 18594062

Auteurs

Charles Thivolet (C)

Department of Endocrinology and Diabetes, Lyon-Sud Hospital, Hospices Civils de Lyon, 69310, Pierre-Bénite, France. charles.thivolet@chu-lyon.fr.
UnivLyon, Inserm, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Oullins, France. charles.thivolet@chu-lyon.fr.

Lucien Marchand (L)

Department of Endocrinology and Diabetes, Lyon-Sud Hospital, Hospices Civils de Lyon, 69310, Pierre-Bénite, France.
UnivLyon, Inserm, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Oullins, France.

Karim Chikh (K)

UnivLyon, Inserm, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Oullins, France.
Department of Biochemistry, Lyon-Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH